IASO Biotechnology Partners with Instituto Butantan to Localise CAR-T Therapy in Brazil
IASO Bio licenses CAR-T technology to Instituto Butantan for local development in Brazil, aiming to reduce treatment costs and expand public access to advanced therapies for haematological cancer patients.
Haematological Cancer | 13/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy